Literature DB >> 33318000

The Polyaminoisoprenyl Potentiator NV716 Revives Old Disused Antibiotics against Intracellular Forms of Infection by Pseudomonas aeruginosa.

Gang Wang1, Jean-Michel Brunel2, Jean-Michel Bolla2, Françoise Van Bambeke3.   

Abstract

Active efflux confers intrinsic resistance to multiple antibiotics in Pseudomonas aeruginosa, including old disused molecules. Beside resistance, intracellular survival is another reason for failure to eradicate bacteria with antibiotics. We evaluated the capacity of polyaminoisoprenyl potentiators (designed as efflux pump inhibitors [EPIs]) NV716 and NV731 compared to PAβN to restore the activity of disused antibiotics (doxycycline, chloramphenicol [substrates for efflux], and rifampin [nonsubstrate]) in comparison with ciprofloxacin against intracellular P. aeruginosa (strains with variable efflux levels) in THP-1 monocytes exposed over 24 h to antibiotics alone (0.003 to 100× MIC) or combined with EPIs. Pharmacodynamic parameters (apparent static concentrations [C s] and maximal relative efficacy [E max]) were calculated using the Hill equation of concentration-response curves. PAβN and NV731 moderately reduced (0 to 4 doubling dilutions) antibiotic MICs but did not affect their intracellular activity. NV716 markedly reduced (1 to 16 doubling dilutions) the MIC of all antibiotics (substrates or not for efflux; strains expressing efflux or not); it also improved their relative potency and maximal efficacy (i.e., lower C s; more negative E max) intracellularly. In parallel, NV716 reduced the persister fraction in stationary cultures when combined with ciprofloxacin. In contrast to PAβN and NV731, which act only as EPIs against extracellular bacteria, NV716 can resensitize P. aeruginosa to antibiotics whether they are substrates or not for efflux, both extracellularly and intracellularly. This suggests a complex mode of action that goes beyond a simple inhibition of efflux to reduce bacterial persistence. NV716 appears to be a useful adjuvant, including to disused antibiotics with low antipseudomonal activity, to improve their activity, including against intracellular P. aeruginosa.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; antibiotic; drug efflux; efflux inhibitor; intracellular bacteria

Mesh:

Substances:

Year:  2021        PMID: 33318000      PMCID: PMC8092510          DOI: 10.1128/AAC.02028-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

Review 1.  Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms.

Authors:  K Poole
Journal:  J Mol Microbiol Biotechnol       Date:  2001-04

2.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.

Authors:  Louis B Rice
Journal:  J Infect Dis       Date:  2008-04-15       Impact factor: 5.226

Review 4.  Antibiotic Adjuvants: Make Antibiotics Great Again!

Authors:  Hana Douafer; Véronique Andrieu; Otto Phanstiel; Jean Michel Brunel
Journal:  J Med Chem       Date:  2019-05-16       Impact factor: 7.446

5.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

6.  Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.

Authors:  O Lomovskaya; M S Warren; A Lee; J Galazzo; R Fronko; M Lee; J Blais; D Cho; S Chamberland; T Renau; R Leger; S Hecker; W Watkins; K Hoshino; H Ishida; V J Lee
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Pseudomonas aeruginosa invades corneal epithelial cells during experimental infection.

Authors:  S M Fleiszig; T S Zaidi; E L Fletcher; M J Preston; G B Pier
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Glycolipid-Dependent, Protease Sensitive Internalization of Pseudomonas aeruginosa Into Cultured Human Respiratory Epithelial Cells.

Authors:  Aufaugh Emam; William G Carter; Clifford Lingwood
Journal:  Open Microbiol J       Date:  2010-12-13

9.  Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models.

Authors:  Valerie Defraine; Laure Verstraete; Françoise Van Bambeke; Ahalieyah Anantharajah; Eleanor M Townsend; Gordon Ramage; Romu Corbau; Arnaud Marchand; Patrick Chaltin; Maarten Fauvart; Jan Michiels
Journal:  Front Microbiol       Date:  2017-12-22       Impact factor: 5.640

10.  Killing from the inside: Intracellular role of T3SS in the fate of Pseudomonas aeruginosa within macrophages revealed by mgtC and oprF mutants.

Authors:  Preeti Garai; Laurence Berry; Malika Moussouni; Sophie Bleves; Anne-Béatrice Blanc-Potard
Journal:  PLoS Pathog       Date:  2019-06-20       Impact factor: 6.823

View more
  2 in total

Review 1.  Synergy by Perturbing the Gram-Negative Outer Membrane: Opening the Door for Gram-Positive Specific Antibiotics.

Authors:  Charlotte M J Wesseling; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-08-10       Impact factor: 5.578

2.  The membrane-active polyaminoisoprenyl compound NV716 re-sensitizes Pseudomonas aeruginosa to antibiotics and reduces bacterial virulence.

Authors:  Gang Wang; Jean-Michel Brunel; Matthias Preusse; Negar Mozaheb; Sven D Willger; Gerald Larrouy-Maumus; Pieter Baatsen; Susanne Häussler; Jean-Michel Bolla; Françoise Van Bambeke
Journal:  Commun Biol       Date:  2022-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.